Association between IGFBP1 expression and cancer risk: A systematic review and meta-analysis.

ABSTRACT

Background: The results regarding the association between insulin-like growth factor binding protein 1 (IGFBP1) expression and cancer risk were controversial. We performed a meta-analysis to provide novel evidence on relationship between IGFBP1 expression and cancer risk. Methods: PubMed, Embase, Cochrane library and Web of science were searched for relevant cohort and case-control studies exploring the relationship between IGFBP1 expression and cancer risk. Odds ratios (ORs) were pooled in this meta-analysis using random model. Subgroup analyses were performed based on ethnicity, tumor types, publication year, study type, Newcastle-Ottawa Scale (NOS) score and sex. Results: A total of 27 studies including 16 cohort and 11 case-control studies were identified by literature search. No significant association was found between IGFBP1 expression and risk of various cancers [0.90, 95% confidence interval (CI) 0.79, 1.03]. The overall results showed that the pooled ORs were 0.71 (95% CI 0.57, 0.88] for prostate cancer risk and 0.66 (95%CI 0.44, 0.99) for colorectal cancer (CRC) risk. However, there is no significant association between IGFBP1 expression and risk for ovarian cancer (1.70, 95%CI 0.41, 6.99), breast cancer (1.02, 95%CI 0.85, 1.23), endometrial cancer (1.19, 95%CI 0.64, 2.21), colorectal adenoma (0.93; 95%CI 0.81, 1.07), lung cancer (0.81, 95%CI 0.39, 1.68) or multiple myeloma (1.20, 95%CI 0.98, 1.47). Conclusion: In this study, compared with individuals at low IGFBP1 expression adjusted for age, smoking status, alcohol intake and so on, risk of the prostate cancer and CRC were decreased among individuals of high IGFBP1 expression. There needs further study to confirm this issue.